A randomized controlled trial comparing the efficacy of denosumab, teriparatide or combination of denosumab and teriparatide on bone microarchitecture in patients being initiated on glucocorticoids

PGIMER0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•1. Age > 18 years
•2. Patients who are being started on glucocorticoids for various therapeutic indications.
•3. Steroid dose > 2.5 mg Prednisone (or equivalent dose of other steroids) per day for at least three months.
•4. Patients who are willing to give informed consent.

•1. Baseline eGFR < 45 ml/min/1.73 m2
•2. Patients who have received steroid dose of more than 2.5 mg per day for more than 3 months in the past 1 year
•3. Pregnant females.
•4. Females with reproductive age group if they will plan for pregnancy for the next 2 years.
•5. Patients with intrinsic bone disorders (FD or Skeletal dysplasia).
•6. Patients on drugs affecting bone health or received anti-osteoporotic therapy
•7. Patients with secondary causes of osteoporosis (Endogenous Cushing Syndrome, Hyperprolactinemia, Primary hyperparathyroidism, CKD, Hypoparathyroidism etc.,)
•8. Patients with structural abnormalities, kyphoscoliosis, hip replacement or surgical implants that may affect DXA study.
•9. History of chronic diseases which can directly affect bone and mineral metabolism, like Rheumatoid arthritis, Ankylosing spondylitis, Marfan syndrome, EDS, Celiac disease, and Inflammatory bowel disease.
•10. Patients who are not willing to give informed consent.

发起方